The Atossa Therapeutics (NASDAQ:ATOS) stock has been one of the major gainers in recent weeks and the strong move in the stock continued on Thursday.
Yesterday, the Atossa stock went up by 13% to takes its gains over the past six weeks to as much as 200%. This week the stock rallied after an analyst marginally his target price. Edward Woo, who has been tracking Atossa for quite some time raised the target price to $8 a share from $7.75 a share.
The new target price was just over double the previous closing price of the Atossa stock at the time. On the other hand, Woo maintained the buy rating on the stock.
The company’s flagship product is Endoxifen, a breast cancer treatment product and since the condition is quite widespread, it is believed that it might have considerable upside. In recent times, the company has also started working on two product meant for the treatment of COVID 19 patients.
Moving Averages
| +/- EMA(20) | 3.20 (+38.75%) |
| +/- SMA(50) | 2.46 (+80.49%) |
| +/- SMA(200) | 2.18 (+103.67%) |
 stock Soars: New High Ahead?){kind=link}